4'-hydroxy-3'-methoxyisoflavone-7

Other Names

3',7-Dihydroxy-4'-methoxyisoflavone3'-Hydroxyformononetin4H-1-Benzopyran-4-one, 7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)-7,3'-Dihydroxy-4'-methoxyisoflavone7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)-1-benzopyran-4-one7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)-4-chromenone7-Hydroxy-3-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one7-Hydroxy-3-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one7-Hydroxy-3-(3-hydroxy-4-methoxyphenyl)benzopyran-4-one7-Hydroxy-3-(3-hydroxy-4-methoxyphenyl)chromen-4-oneAstraisoflavoneCalycosinCyclosinIsoflavone, 3',7-dihydroxy-4'-methoxy-

Synopsis

4′-Hydroxy-3′-methoxyisoflavone-7 (Calycosin): A Comprehensive Reference

1. Identity: Chemical Names, Structure, and Synonyms

4′-Hydroxy-3′-methoxyisoflavone-7 is the systematic positional name for the compound commonly known as calycosin. Its molecular formula is C₁₆H₁₂O₅ and it is formally designated as 7,3′-dihydroxy-4′-methoxyisoflavone. Its IUPAC name is 7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)-chromen-4-one.

Calycosin is an O-methylated isoflavone. It belongs to the family of 7-hydroxy isoflavones, in which an extra hydroxy group replaces the 3′ position and a methoxy group occupies the 4′ position. It is thus simultaneously a member of 7-hydroxy isoflavones and a member of 4′-methoxyisoflavones. It has a topological polar surface area of 76 Å², 21 heavy element counts, one chemically bound unit, and no formal charge. The molecular weight of calycosin is 284.26 g/mol, and in its pure form it presents as a white to off-white powder.

The CAS registry number for calycosin is 20575-57-9. In its pure form, calycosin is a white needle-like crystal that displays poor solubility in water and various organic solvents, including ethanol, methanol, and chloroform. It also shows poor solubility in acetone and dichloromethane.

The compound is biosynthetically derived from the isoflavone precursor formononetin. Isoflavone 3′-hydroxylase uses formononetin, NADPH, H⁺, and O₂ to produce calycosin, NADP⁺, and H₂O. This enzymatic hydroxylation at the 3′ position of the B-ring of formononetin is the key biosynthetic step distinguishing calycosin from its precursor.

2. Botanical Sources and Natural Occurrence

Calycosin is a natural compound belonging to the isoflavone class of phytochemicals. It can be found in various plant sources, primarily within the Fabaceae (legume) family, including Thermopsis lanceolata and Hedysarum polybotrys.

Calycosin is a bioactive phytoestrogen isoflavone extracted from traditional Chinese medicinal plants such as Astragalus membranaceus, Hedysarum polybotrys, Glycyrrhiza glabra, and Spatholobi Caulis, with the highest content of calycosin found in Astragalus membranaceus.

This bioactive chemical compound is mainly found in the desiccated root infusion of several medicinal plants, including Radix astragali (Astragalus propinquus), Trifolium pratense L. (red clover), Astragalus falcatus, A. microcephalus, T. fabacea, A. membranaceus Fisch. (Bunge), Wisteria brachybotrys, Thermopsis californica, Thermopsis lanceolata, Bowdichia nitida, Styphnolobium japonicum, Mucuna membranacea, Andira surinamensis, Myroxylon peruiferum, Calycotome villosa, and Oxytropis falcata.

Calycosin is the most enriched isoflavone found abundantly in Astragalus membranaceus (Huangqi in Chinese), a classic traditional herbal medicine commonly used in a variety of traditional Chinese medicine prescriptions.

The chemical composition of Astragalus is complex and mainly includes flavonoids, saponins, and polysaccharide compounds, as well as amino acids and trace elements. To date, more than 200 compounds have been isolated from Astragalus species, among which isoflavones such as calycosin (CAL), calycosin-7-glucoside (CG), formononetin (FMN), and ononin (ON) have significant value because of their antioxidant, anticancer, anti-inflammatory, and neuroprotective pharmacological effects.

3. Traditional and Historical Use

The traditional use of calycosin is inseparable from its botanical host plant, Astragalus membranaceus (Huangqi), which has been extensively documented in classical Chinese medical texts. The application of Huangqi can be traced back to the Han Dynasty and was first recorded in Shennong Ben Cao Jing (Han Dynasty, 202 BCE–220 CE), where it was categorized as a high-quality product. Li Shizhen's Compendium of the Materia Medica (Ming Dynasty, AD 1552–1578) lists Huangqi as the first tonic herb, which mainly reinforced healthy Qi, dispelled pathogenic factors, promoted diuresis, and reduced swelling.

Huangqi has been prevalent for more than 2,000 years with over 200 types of herbal decoctions and has experienced extensive clinical application in Chinese medicine. It has long been used as an ethnomedicine in the Russian Federation, Mongolia, Korea, Kazakhstan, and China. It was first recorded in the Shennong Ben Cao Jing and includes the effects of reinforcing healthy Qi, dispelling pathogenic factors, promoting diuresis, reducing swelling, activating blood circulation, and dredging collaterals.

Astragali Radix (AR), originally recorded in Shennong's Herbal, is widely utilized in the prevention and treatment of clinical cardiovascular and cerebrovascular disorders.

The major pharmaceutical functions of this Materia Medica in Chinese medicine are boosting immune and hematopoietic systems. For more than 2,000 years it has been one of the most widely used Chinese herbal medicines and also used as a functional food for reinforcing "Qi" (vital energy). It is traditionally used for revitalizing, tonifying, skin reinforcement, diuretic, abscess-draining, and tissue-generative purposes.

Calycosin itself was not isolated as a discrete chemical entity in traditional usage; rather, its therapeutic effects were historically realized through root decoctions, dried powders, and water extracts of the whole herb. Radix astragali (Fabaceae Astragalus propinquus Schischkin) is a Chinese medicinal herb traditionally used for the treatment of several diseases; calycosin is the major bioactive chemical in the dry root extract of this medicinal plant. Astragaloside IV and calycosin 7-O-β-D-glucoside (CG) are used as markers for quality control of AR and its products in the Chinese Pharmacopoeia.

4. Key Constituents, Common Forms, and Preparations

Calycosin occurs naturally in plants primarily in two forms: the aglycone (free form) and its glycoside conjugate. The pharmacokinetic profiles of calycosin and its glucoside differ significantly, which impacts their bioavailability and therapeutic efficacy. After oral administration, calycosin-7-O-β-D-glucoside can be partially absorbed in its intact form and is also hydrolyzed to calycosin by intestinal microflora.

In the raw materials, malic acid esters of calycosin-7-glucoside are easily decomposed into the glucoside form during storage and processing of AR to make extracts for various preparations. The thermal stability of the isoflavonoids in decoction was studied; the level of calycosin-7-glucoside was strongly affected by prolonged heat during processing, while calycosin (the aglycone) itself was stable under such conditions.

As the main bioactive molecule isolated from Astragali Radix, the pharmacological activity of calycosin is not performed alone but by the joint action of multiple chemical substances. Co-treatment of calycosin with other biochemicals identified from Astragali Radix — namely formononetin, ononin, and astragaloside — showed effective therapeutic functions as compared to single compound administration.

In contemporary commercial and research contexts, calycosin is available as a purified isolate (typically ≥98% purity) for research purposes, as standardized dry root extracts of Astragalus membranaceus in capsule or tablet form, and as a component of traditional herbal decoctions. Therapies based on nano-formulated calycosin may make excellent nanocarriers for the delivery of this compound to targeted tissue as well as particular organs.

5. Active Compounds and Mechanisms of Action

5.1 Phytoestrogenic and Estrogen Receptor Interactions

Calycosin is a main active component of the herb Radix Astragali and is considered a phytoestrogen. Its effects in vivo may be either estrogenic or antiestrogenic, mainly depending upon the estrogen levels present in the local environment.

Calycosin interacts with both major subtypes of the estrogen receptor. The estrogen receptor belongs to the steroid hormone receptor family and contains two subtypes: ER alpha (ERα) and ER beta (ERβ). The balance between the levels of ERα and ERβ affects cellular proliferation, with a higher ratio of ERα to ERβ promoting cell growth and a lower ratio suppressing it. Tumor tissues typically express lower levels of ERβ, and some cancers related to estrogen dependence — such as colorectal, breast, and renal cell cancers — may act through ERβ. These findings suggest that ERβ may have a tumor-suppressive role and may be a potential target for cancer therapy.

Pretreatment with ICI 182,780, an estrogen receptor inhibitor, negated the protective effect of calycosin against oxidative stress-induced apoptosis. Akt phosphorylation was upregulated by calycosin alone and downregulated by co-treatment with calycosin and ICI 182,780. These data demonstrated that calycosin exhibits anti-apoptotic effects by activating ERα/β and enhancing Akt phosphorylation in cardiomyocytes.

5.2 PI3K/Akt/mTOR Signaling

Previously reported studies on the mechanisms of the antitumor effects of calycosin exist. Among these, the PI3K/AKT signaling pathway has been shown to have a role in the functional mechanism of the effects of calycosin. This pathway governs cell survival, proliferation, and apoptosis across multiple cell types. Calycosin, when administered to estrogen-receptor-positive human osteosarcoma cell line MG-63, had anti-proliferative and pro-apoptotic effects. At the molecular level, calycosin achieved these effects through the PI3K/AKT/mTOR signaling pathway, in which PI3K was identified as the key protein.

5.3 MAPK / ERK1/2 Signaling

One major study investigated calycosin's promotion of the proliferation of estrogen receptor-positive cells via ERs and ERK1/2 activation in vitro and in vivo, using ER-positive MCF-7 (human breast cancer) cells treated with different concentrations of calycosin. Compared with the control, low concentrations of calycosin (2–8 μM) stimulated the proliferation of MCF-7 cells. Furthermore, an ERK1/2 inhibitor significantly blocked the effect of calycosin in MCF-7 cells. In the in vivo studies, calycosin stimulated a dramatic increase in uterine weight and downregulated the level of ERα protein in ovariectomized mice. This study demonstrated that at relatively low concentrations calycosin had stimulatory effects on the proliferation of MCF-7 cells due to its estrogenic effect.

5.4 NF-κB and MAPK Inhibition in Inflammatory Pathways

Calycosin, an isoflavonoid phytoestrogen isolated from Radix Astragali, was reported to possess anti-tumor, anti-inflammation, and osteogenic properties. Results indicated that calycosin down-regulated the expression levels of NFATc1 and c-Fos through suppressing the activation of NF-κB and MAPKs. These results indicate that calycosin has an inhibitory role in bone loss by preventing osteoclast formation, as well as its bone resorptive activity.

5.5 Antioxidant Mechanisms

Calycosin has been revealed to attenuate oxidative stress by decreasing malondialdehyde (MDA), protein carbonyl, and reactive oxygen species (ROS) while promoting the function of glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD).

5.6 TRPC6-CREB Neuroprotective Pathway

Treatment with calycosin protected against ischemia-induced damage by increasing TRPC6 and P-CREB expression and inhibiting calpain activation. The neuroprotection effect of calycosin was diminished by inhibition or knockdown of TRPC6. These findings indicated that the potential neuroprotection mechanism of calycosin involves the TRPC6-CREB pathway.

5.7 HMGB1/TLR4/NF-κB Neuroinflammatory Signaling

Calycosin mitigates cerebral ischemia-reperfusion injury and neuroinflammation by inhibiting the HMGB1/TLR4/NF-κB signaling pathway, thereby providing neuroprotection.

5.8 NLRP3 Inflammasome Inhibition

Calycosin significantly reduced neurological impairments and brain infarction in a dose-dependent manner, alleviated neuronal damage, and decreased the expression of pyroptosis-related markers, including NLRP3, GSDMD, HMGB1, IL-1β, IL-18, and caspase-1. These results indicate that calycosin enhances microglial cell survival and mitigates pyroptotic damage by inhibiting NLRP3 inflammasome activation, suggesting its potential as a neuroprotective therapy for ischemic stroke through the modulation of the HMGB1-dependent pyroptosis pathway.

6. Scientific Evidence by Area of Use

The existing body of research for calycosin is composed almost entirely of in vitro (cell culture), in vivo (animal model), and computational (in silico) studies. Robust human clinical trial evidence is very limited, and this limitation is explicitly acknowledged by the research community. Despite promising findings, further research, including detailed mechanistic studies and clinical trials, is needed to fully understand calycosin's therapeutic mechanisms and validate its potential in human subjects.

6.1 Oncology / Anti-Cancer Activity

Based on published reviews, calycosin is effective against around 15 different types of cancer. Generally, the anti-cancer mechanism of this compound is mediated through a variety of processes, including regulation of apoptotic pathways, cell cycle, angiogenesis and metastasis, oncogenes, enzymatic pathways, and signal transduction processes. These studies were conducted in various models, including in silico, in vitro, preclinical, and clinical models.

Breast Cancer. Calycosin inhibited the proliferation of both ER-negative (MDA-MB-468 and SKBR3) and ER-positive breast cancer cells (MCF-7 and T47D), and these inhibitory effects were associated with the up-regulation of the long non-coding RNA (lncRNA) WDR7-7. The expression of WDR7-7 is reduced in breast cancer cell lines, and the overexpression of WDR7-7 inhibits growth through a mechanism that involves G-protein coupled estrogen receptor 30 (GPR30). Calycosin at 150 μM was capable of blocking MCF-7 and T47D cell migration and invasion by wound healing and Transwell assays. Calycosin at 2 μmol/L already triggered MCF-7 cell apoptosis by flow cytometry analysis. Additionally, treatment with calycosin could downregulate forkhead box P3, vascular endothelial growth factor (VEGF), and matrix metalloproteinase 9 (MMP9) in MCF-7 and T47D cells. Importantly, cellular and molecular studies revealed that calycosin did not induce a significant cytotoxic effect on the viability of normal human breast epithelial cells (MCF-10A) even at 200 μM concentration, at which it was able to inhibit the proliferation of breast cancer MDA-MB-231 cells. Evidence strength: preclinical (in vitro and animal models); no completed human clinical trials identified.

Colorectal Cancer. One study analyzed the effect of calycosin on the viability and apoptosis of human CRC HCT116 and SW480 cells via MTT assay, flow cytometry assay, and caspase-3/7 activity assay. The protein expressions of ERβ, PTEN, and PI3K/Akt signal pathways were determined by Western blot analysis. Alterations of biological behavior in CRC cells transfected with ERβ siRNA were analyzed. Mouse xenograft models were further performed to detect the antitumor effect in vivo. The results show that calycosin reduces CRC cell viability, induces cell apoptosis, and suppresses xenograft tumor growth. In vitro assays and transcriptome sequencing confirmed that calycosin effectively suppresses migration, invasion, epithelial-mesenchymal transition (EMT), and induces ferroptosis in human CRC cells. Cellular thermal shift assay (CETSA) and site-directed mutagenesis experiments first identified cytochrome P450 1B1 (CYP1B1) and Gly-329 as critical binding targets and sites for calycosin. Evidence strength: preclinical only.

Osteosarcoma. In one study, calycosin treatment significantly reduced cell viability and increased the apoptosis rate in ER-positive osteosarcoma MG-63 cells, with no impact on cell proliferation or apoptosis of ER-negative osteosarcoma U2-OS cells. Evidence strength: preclinical only.

Leukemia (erythroleukemia). One study investigated the effects of total flavonoids of Astragalus (TFA) and calycosin on apoptosis induction and cell cycle of the human erythroleukemia cell line K562 using MTT, PI staining, and Annexin V/PI double staining. Both TFA and calycosin could inhibit the proliferation of K562 cells, with an IC50 for calycosin of 130.32 μg/mL. However, neither TFA nor calycosin could induce apoptosis in K562 cells, though both increased the number of cells in the G₀/G₁ phase. Evidence strength: in vitro only.

Lung Adenocarcinoma. Findings from a multi-omics investigation reveal that calycosin exerts inhibitory effects on lung adenocarcinoma (LUAD) cell proliferation, migration, and invasion while simultaneously inducing apoptosis and reversing EMT. Notably, these effects were more pronounced in advanced-stage LUAD models, suggesting that calycosin may serve as a stage-specific anticancer agent. Evidence strength: in silico and preclinical; no human data.

Furthermore, calycosin has been shown to enhance the efficacy of certain chemotherapeutic drugs, making it a potential component in treating malignant tumors. Given its high efficacy, low toxicity, and multi-targeting characteristics, CA holds considerable promise as a therapeutic agent for cancer treatment. However, the evidentiary base for all these claims remains preclinical, and no large-scale randomized controlled trials in humans have been completed.

6.2 Neuroprotection and Neurological Conditions

Cerebral ischemia-reperfusion injury (CIRI) is a key pathophysiological process that leads to stroke mortality, with TLR4-mediated inflammation playing a crucial role. Previous research highlighted the neuroprotective effects of calycosin on CIRI.

All published data reveal that calycosin exerts a neuroprotective effect on cerebral ischemia and reperfusion injury, and the mechanisms may be associated with its anti-autophagic, anti-apoptotic, and anti-inflammatory actions.

One study was designed to test whether calycosin protects against cerebral ischemic injury through the TRPC6-CREB pathway. In vivo, rats were subjected to transient middle cerebral artery occlusion (MCAO) for 2 hours and then treated with different doses of calycosin at the onset of reperfusion. In vitro, primary cultured neurons were treated with calycosin, then exposed to 2-hour oxygen-glucose deprivation (OGD) followed by 24-hour reoxygenation. Results showed that treatment with calycosin protected against ischemia-induced damage by increasing TRPC6 and P-CREB expression and inhibiting calpain activation.

Calycosin, a biologically active isoflavonoid derived from Astragali Radix, has demonstrated neuroprotective potential in CIRI through anti-oxidation, anti-calcium overload, anti-ferroptosis, and suppression of microglial overpolarization.

Evidence strength for neuroprotection: almost entirely animal (rodent MCAO model) studies with some in vitro data. No clinical trials in stroke or neurodegeneration patients have been reported.

6.3 Cardiovascular Protection

As an O-methylated isoflavone, calycosin has the potential to treat malignant cancers, inflammatory diseases, ischemia, and cardiovascular disorders.

The anti-atherosclerosis efficacy of calycosin has been unveiled in recent years. Calycosin enhances macrophage autophagy to improve high-fat diet-caused atherosclerosis. Calycosin activates the AMPK/mTOR signaling to ameliorate autophagy stoppage in smooth muscle cells and mitigate vascular calcification.

Studies in cardiomyocyte models indicate that calycosin exhibits anti-apoptotic effects by activating ERα/β and enhancing Akt phosphorylation in cardiomyocytes.

Evidence strength: preclinical (cell and animal models); no human cardiovascular trial data available.

6.4 Bone Health: Osteoporosis and Osteoarthritis

Calycosin significantly inhibited RANKL-induced osteoclast formation from primary bone marrow macrophages (BMMs). It also dose-dependently suppressed the formation of bone resorption pits by mature osteoclasts. In addition, the expression of osteoclastogenesis-related genes, including cathepsin K (CtsK), tartrate-resistant acid phosphatase (TRAP), and MMP-9, was significantly inhibited by calycosin.

Results indicate that calycosin has an inhibitory role in bone loss by preventing osteoclast formation as well as its bone resorptive activity. Therefore, calycosin may be useful as a therapeutic reagent for bone loss-associated diseases.

Calycosin has been reported to have strong osteogenic activity; it can inhibit bone resorption and stimulate bone formation. Another study shows that calycosin plays an anti-osteoporosis effect through the IGF1R/PI3K/Akt signaling pathway.

In an osteoarthritis model, calycosin, as the main active component of Astragalus mongholicus Bunge, exhibits anti-inflammatory action in OA. Using an anterior cruciate ligament transection (ACLT) mouse model, with mice randomized to sham, OA, and calycosin groups, cartilage synthesis markers type II collagen (Col-2) and SRY-Box Transcription Factor 9 (Sox-9) increased significantly after calycosin gavage.

Evidence strength: preclinical (cell culture and animal models); no clinical trial data in humans with osteoporosis or osteoarthritis.

6.5 Anti-Inflammatory Activity Across Organ Systems

Calycosin's potential therapeutic breadth spans eight pathological arenas, including cardiovascular, articular, gastrointestinal, genitourinary, neurological, cutaneous, infectious, and neoplastic areas, while its anti-inflammatory efficacy across these domains has been systematically reviewed.

Calycosin, a functional phytoestrogen, is pharmacologically beneficial due to its neuroprotection, cytoprotection, antioxidative, hypolipemic, and hypoglycemic effects.

In the context of liver fibrosis, results showed that calycosin inhibited the proliferation of activated hepatic stellate cells (HSCs) and remarkably inhibited HSC migration. Calycosin significantly reduced the expression of α-SMA and COL-I in activated HSCs. However, with co-treatment with ICI 182,780 (an estrogen receptor antagonist), the inhibitory effect of calycosin against these effects was strongly negated, indicating an estrogen-receptor-dependent mechanism in hepatic anti-fibrotic effects.

Evidence strength: The anti-inflammatory evidence base is predominantly in vitro and animal; comprehensive human clinical trials are absent.

6.6 Metabolic and Glycemic Effects

Calycosin and its glucoside exhibit a wide range of biological activities, including anti-inflammatory, neuroprotective, anticancer, and α-glucosidase inhibitory effects. A direct comparative study has shown that calycosin is a significantly more potent inhibitor of α-glucosidase than its glucoside counterpart, suggesting a potential role in carbohydrate metabolism. Evidence strength: in vitro biochemical data only; no clinical evidence in diabetes patients.

7. Dosage Forms and Study-Reported Dosages

Calycosin is studied both as an isolated compound and as a component of Astragalus root extracts. The dosages reported in the peer-reviewed literature reflect experimental conditions rather than established clinical recommendations for humans.

Cultured ER-positive MG-63 human osteosarcoma cells and ER-negative U2-OS human osteosarcoma cells were treated with increasing doses of calycosin: 0, 25, 50, and 100 μM in the in vitro arm of one study.
Low concentrations of calycosin at 2–8 μM stimulated the proliferation of MCF-7 cells in vitro.
Calycosin at 150 μM was capable of blocking MCF-7 and T47D cell migration and invasion in wound healing and Transwell assays.
Under OGD/R conditions, calycosin was evaluated in microglial HAPI cells at varying dosages of 1–4 μM; calycosin provided neuroprotection in the OGD/R model, with effectiveness varying according to dosage.
In an in vivo MCAO rat model, calycosin was found to protect against cerebral ischemia-reperfusion injury within the range of 5–20 mg/kg body weight.
The 50% inhibiting concentration (IC₅₀) of calycosin against K562 human erythroleukemia cells was 130.32 μg/mL in vitro.
In the Chinese Pharmacopoeia, calycosin-7-O-β-D-glucoside (CG) — the glycoside form — serves as a quality control marker for Astragali Radix and its products.

No standardized human clinical dosing regimen for isolated calycosin has been established or published in accessible peer-reviewed literature as of the time of writing.

8. Pharmacokinetics and Bioavailability

The pharmacokinetic profiles of calycosin and its glucoside differ significantly. After oral administration, calycosin-7-O-β-D-glucoside can be partially absorbed in its intact form and is also hydrolyzed to calycosin by intestinal microflora.

To confirm the hydrolysis site of calycosin-7-O-β-glucoside, the pharmacokinetics of calycosin-7-O-β-glucoside injection in rats were investigated, since the drug was directly absorbed by the hepatic portal vein after intraperitoneal injection, thereby excluding the effect of the intestine. The results show that the drug-time curve of calycosin-7-O-β-glucoside and its metabolites is completely different from that of calycosin-7-O-β-glucoside after oral administration, confirming the importance of intestinal enzymatic hydrolysis in the conversion to the active aglycone.

The blood-brain barrier (QPlogBB) is essential for drugs targeting brain disorders. In silico prediction indicates that calycosin has poor potential to cross the blood-brain barrier and enter the central nervous system. This represents a significant pharmacokinetic challenge given that several proposed therapeutic applications involve neurological targets.

Calycosin showed better pharmacokinetic properties with less toxicity in human bodies compared to many synthetic agents, according to one published review, though this claim is based primarily on in silico ADMET modeling rather than clinical pharmacokinetic studies.

9. Safety Considerations and Drug Interactions

9.1 General Toxicological Profile

With its high targeting and low toxicity profile, calycosin has demonstrated medicinal potential across various diseases. Preclinical data suggest a favorable safety margin for normal, non-cancerous cells. Cellular and molecular studies revealed that calycosin did not induce a significant cytotoxic effect on the viability of normal human breast epithelial cells (MCF-10A), even at 200 μM concentration.

In silico prediction reported that calycosin is a substrate for most CYP450 subunits, including CYP1A2, CYP2C9, and CYP2D6. Calycosin's in silico toxicity profile predicted potential hepatotoxicity, cardiotoxicity, skin sensitization, kidney toxicity, and eye irritation; however, it did not show AMES toxicity (mutagenicity) in silico. These predictions are computational and await clinical validation.

9.2 CYP450 Enzyme Interactions and Drug-Drug Interaction Risk

Calycosin exhibits therapeutic activity against multiple disease states and may be effectively combined with other clinical treatments; however, the mechanisms underlying its metabolism in vivo are yet to be fully established. Accordingly, caution is recommended, particularly when combining calycosin as a modality therapy with drugs metabolized by CYP1A2, CYP2D6, and CYP2C9, to reduce the risk of drug interactions.

The CYP450 enzyme detoxifies more than 80% of medications during hepatic first-pass metabolism, and blocking this enzyme increases drug potency and several adverse effects. Predicted metabolic results reported that calycosin is a substrate for most CYP450 subunits, including CYP1A2, CYP2C9, and CYP2D6.

9.3 Estrogenic Activity and Estrogen-Sensitive Conditions

Calycosin is considered a phytoestrogen, and its effects in vivo may be either estrogenic or antiestrogenic, mainly depending upon the ambient estrogen levels. This bidirectional estrogenicity has direct implications for safety: in low-estrogen environments (such as postmenopausal women), calycosin may exert estrogenic effects, while in high-estrogen environments it may act as an antagonist. Phytoestrogens warrant investigation in breast cancer research because they are structurally similar to estrogen and exert estrogenic effects on breast cancer cells in low-estrogen environments but antiestrogenic effects in high-estrogen environments.

Low concentrations of calycosin promoted cell proliferation in endothelial cell lines (HUVECs and HMEC-1 cells) and in breast cancer cells expressing ERα (MCF-7 and T47D). One possible reason for this finding is that calycosin has estrogenic or antiestrogenic effects depending on the presence of estrogen. The dual estrogenic/antiestrogenic dose-response and context-dependency is a critical consideration for any use in individuals with hormone-sensitive conditions.

9.4 Limitations of the Safety Evidence Base

The absence of completed Phase I or Phase II human clinical trials means that the full human safety and tolerability profile of isolated calycosin — including dose-response, adverse event rates, and drug interaction risks — has not been formally characterized in the clinical setting. Further research, including detailed mechanistic studies and clinical trials, is needed to fully understand calycosin's therapeutic mechanisms and validate its potential in human subjects.

10. Summary of Evidence Strength

The research landscape for calycosin (4′-hydroxy-3′-methoxyisoflavone-7) is characterized by a substantial volume of preclinical data across multiple disease areas, but a very limited clinical evidence base. The potential pharmaceutical properties of calycosin in the treatment of tumors, inflammation, stroke, and cardiovascular diseases have gained increasing attention in recent years. However, the translation of these findings to human clinical applications has not yet been demonstrated through well-designed, adequately powered randomized controlled trials. The literature survey showed that calycosin exhibits promising effects for the treatment of several diseases and that these effects may be due to its isoflavonoid and phytoestrogenic properties, but this remains a research-stage compound for the majority of its proposed therapeutic uses. The compound's poor water solubility, complex estrogenic/antiestrogenic duality, CYP450 substrate status, and limited blood-brain barrier penetration represent key pharmacological challenges that remain to be addressed in translational research.

References

Health Conditions

Health conditions that 4'-hydroxy-3'-methoxyisoflavone-7 may help support.

No conditions available.

Body Systems

Body systems that 4'-hydroxy-3'-methoxyisoflavone-7 may help support.

No body systems available.